Assessment of neuropathic pain in cancer patients

Current Pain and Headache Reports

Volumn 13, Issue 4, 2009, Pages 282-287

  Blumenthal, Deborah T ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CALCIUM; CAPECITABINE; CARBAMAZEPINE; CISPLATIN; CYTARABINE; DOCETAXEL; DULOXETINE; FLUOROURACIL; GABAPENTIN; GLUTAMINE; IMMUNOGLOBULIN; LEVACECARNINE; MAGNESIUM; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXALIPLATIN; PACLITAXEL; PARACETAMOL; PREGABALIN; STEROID; TAXANE DERIVATIVE; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VINCRISTINE;

ALTERNATIVE MEDICINE; ATAXIA; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; CONSTIPATION; CRANIAL NEUROPATHY; DRUG DOSE INCREASE; DYSESTHESIA; ELECTROMYOGRAPHY; EXERCISE; HEMATOLOGIC MALIGNANCY; HUMAN; ILEUS; KAPOSI SARCOMA; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MASSAGE; MEDICAL SPECIALIST; MONONEUROPATHY; MOTOR NEUROPATHY; MULTIPLE MYELOMA; NERVE BIOPSY; NERVE CONDUCTION; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PROGNOSIS; PROTECTIVE CLOTHING; QUALITY OF LIFE; RATING SCALE; REVIEW; SEDATION; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; TESTIS CANCER; XEROSTOMIA;

HUMANS; NEOPLASMS; NEURALGIA; PAIN;

EID: 67651095602     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0045-6     Document Type: Review

References (33)

1. Park SB, Krishnan AV, Lin CS, et al.: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15: 3081-3094.
2. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, et al.: Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990, 66: 1697-1702.
3. Strumberg D, Brügge S, Korn MW, et al.: Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002, 13: 229-236.
4. Davies JM, Goldberg RM: First-line therapeutic strategies in metastatic colorectal cancer. Oncology 2008, 22: 1470-1479.
5. Kowalski T, Maier C, Reinacher-Schick A, Schlegel U: Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options. Schmerz 2008, 22: 16-23.
6. Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10: 4055-4061.
7. Wolf S, Barton D, Kottschade L, et al.: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 2008, 44: 1507-1515.
8. Grothey A, Goldberg RM: A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004, 5: 2159-2170.
9. McWhinney SR, Goldberg RM, McLeod HL: Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009, 8: 10-16.
10. Flatters, SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain 2006, 122: 245-257.
11. Freilich RJ, Balmaceda C, Seidman AD, et al.: Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996, 47: 115-118.
12. Scaioli V, Caraceni A, Martini C, et al.: Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. Neurooncol 2006, 77: 79-87.
13. Rose PG, Smrekar M: Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol Oncol 2003, 91: 423-425.
14. Jin HW, Flatters SK, Xiao WH, et al.: Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008, 210: 229-233.
15. Wang WS, Lin JK, Lin TC, et al.: Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12: 312-319.
16. Stubblefield MD, Vahdat LT, Balmaceda CM, et al.: Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005, 17: 271-276.
17. Hildebrandt G, Holler E, Woenkhaus M, et al.: Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 2000, 11: 743-747.
18. Tarlaci S: Vincristine-induced fatal neuropathy in non-Hodgkin's lymphoma. Neurotoxicology 2008, 29: 748-749.
19. Fine HA, Figg WD, Jaeckle K, et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000, 18: 708-715.
20. Saif MW, Wood TE, McGee PJ, et al.: Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004, 15: 767-771.
21. Baker WJ, Royer GL Jr, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 1991, 9: 679-693.
22. Ocean AJ, Vahdat LT: Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004, 12: 619-625.
23. Spina E, PerugiIG: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004, 6: 57-75.
24. Visovsky C, Meyer RR, Roller J, et al.: Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs 2008, 12: 243-247.
25. Vital A, Lagueny A, Ferrer X, et al.: Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol 2008, 27: 96-110.
26. Vallat JM, Magy L, Richard L, et al.: Intranervous immunoglobulin deposits: An underestimated mechanism of neuropathy. Muscle Nerve 2008, 38: 904-911.
27. Shibata-Hamaguchi A, Samuraki M, Furui E, et al.: B-cell neurolymphomatosis confined to the peripheral nervous system. J Neurol Sci 2007, 260: 249-252.
28. Galán Gil S, Peñarrocha Diago M, Peñarrocha Diago M: Malignant mental nerve neuropathy: Systematic review. Med Oral Patol Oral Cir Bucal 2008, 13: E616-E621.
29. DeAngelis LM, Posner JB: Neurologic Complications of Cancer, edn 2. New York: Oxford University Press; 2008:302-310.
30. Lederman RJ, WiRbourn AJ: Brachial plexopathy: recurrent cancer or radiation. Neurology 1984, 34: 1331-1335.
31. Camdessanché JP, Antoine JC, Honnorat J, et al.: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002, 125: 166-175.
32. Ansari J, Nagabhushan N, Syed R, et al.: Small cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: Case report and literature review. Clin Oncol (R Coll Radiol) 2004, 16: 71-76.
33. National Cancer Institute: Common terminology criteria for adverse events. Available at http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev4.pdf. Accessed March 2009.